Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.80 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.80 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587163 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549584 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549893 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL28436535 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549582 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL22024698 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15550912 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549892 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549891 | 1.00 | PTGER4 (0.80) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549258 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | MYOMETRICS, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2019-03-28 | — | — | US | claimed |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | MYOMETRICS, LLC (US) | 2017-09-14 | — | — | US | claimed |
| US-9701630-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-07-11 | — | — | US | claimed |
| EP-3175852-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-06-07 | — | — | EP | claimed |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-11-24 | — | — | US | claimed |
| EP-2874620-B1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | claimed |
| EP-2875022-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-9440919-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-09-13 | — | — | US | claimed |
| US-9180116-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-06-25 | — | — | US | claimed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | claimed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9180116-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 5/4885PTGER3 3/4885 |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 5/4885PTGER3 4/4885 |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 5/4885PTGER3 3/4885 |
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 5/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.